Recruiting Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL NCT07494565 Conditions CD5 Positive, Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, +10 more Locations Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China View Trial Details
Active, Not Recruiting Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT03946878 Conditions Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, +16 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
